Company Profile

Mesoblast Limited

Level 1, 843A Glenhuntly Road

Caulfield South VIC 3162 Australia
Phone: 03-9618-7000 Fax:

Industry
Biotechnology

Segment
Research and Development

Company News

Mesoblast (MSB.AX) And Mallinckrodt (MNK) Enter Into Equity Purchase Agreement To Exclusively Negotiate Development And Commercialization Of Mesoblast's Cell Therapy Products For Chronic Low Back Pain And Acute Graft Versus Host Disease 12/27/2016 3:48:51 PM

Mesoblast (MSB.AX) Plans to Reduce FY17 Cash Burn to Fund Clinical Operations and Phase III Heart Failure Trial 7/1/2016 9:17:18 AM

Mesoblast (MSB.AX) Stock Sinks 42% After Teva (TEVA) Withdraws from Heart Failure Trials 6/14/2016 6:42:01 AM

Mesoblast (MSB.AX) Provides Strategic Update And Reports On First Quarter Financial Results 12/17/2015 8:03:54 AM

Mesoblast (MSB.AX)’s Japan Licensee Receives Pricing For TEMCELL HS Inj. For Treatment Of Acute Graft Versus Host Disease 11/30/2015 7:19:20 AM

Mesoblast (MSB.AX) Lists On Nasdaq 11/16/2015 7:58:00 AM

Mesoblast (MSB.AX) Announces Pricing Of Public Offering On Nasdaq 11/13/2015 7:22:41 AM

Mesoblast (MSB.AX) Release: Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions 10/28/2015 7:21:02 AM

Mesoblast (MSB.AX) Chairman's Address To 2015 Annual General Meeting 10/22/2015 8:31:37 AM

Celgene (CELG) And Mesoblast (MSB.AX) Extend Agreement 10/16/2015 7:48:56 AM

//-->